Submit your email to push it up the queue
PharMingen, a division of BD Biosciences, is a leading player in the biotechnology industry, headquartered in the United States. Established in the early 1990s, the company has made significant strides in the development of innovative solutions for cell biology and immunology research. With a strong focus on flow cytometry, PharMingen offers a comprehensive range of reagents, instruments, and software that are essential for advanced cellular analysis. Renowned for its high-quality monoclonal antibodies and unique assay kits, PharMingen stands out in the market for its commitment to scientific excellence and customer support. The company has achieved notable recognition for its contributions to research and diagnostics, solidifying its position as a trusted partner for laboratories worldwide. With a robust presence in North America and Europe, PharMingen continues to drive advancements in life sciences, empowering researchers to unlock new discoveries.
How does PharMingen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PharMingen's score of 67 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PharMingen, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Becton, Dickinson and Company, which may influence its climate commitments and reporting practices. PharMingen's climate initiatives and reduction targets are inherited from its parent company, Becton, Dickinson and Company. This includes participation in various sustainability initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for PharMingen itself are not detailed. As part of its corporate family, PharMingen aligns with Becton, Dickinson and Company's broader climate strategies, which may include commitments to reduce emissions across Scope 1, 2, and 3 categories. Nonetheless, without specific data or targets available for PharMingen, the company's individual climate commitments remain unclear.
Access structured emissions data, company-specific emission factors, and source documents
2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 96,333,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 514,801,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 158,622,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PharMingen is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.